Andra AP fonden Has $28.34 Million Stock Position in Cencora, Inc. (NYSE:COR)

Andra AP fonden increased its position in shares of Cencora, Inc. (NYSE:COR) by 11.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,800 shares of the company’s stock after acquiring an additional 13,000 shares during the quarter. Andra AP fonden owned about 0.06% of Cencora worth $28,343,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC acquired a new position in Cencora during the 2nd quarter valued at about $655,000. TD Asset Management Inc bought a new position in Cencora in the first quarter valued at approximately $95,313,000. LSV Asset Management acquired a new stake in Cencora during the 1st quarter worth $3,579,000. Cairn Investment Group Inc. bought a new stake in shares of Cencora during the 1st quarter valued at $2,294,000. Finally, Lake Street Advisors Group LLC bought a new stake in shares of Cencora during the 1st quarter valued at $836,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on COR. Leerink Partners reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Wells Fargo & Company upped their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Finally, Robert W. Baird lowered their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $258.13.

Cencora Price Performance

Shares of NYSE COR opened at $236.53 on Tuesday. The company has a fifty day moving average price of $232.44 and a 200 day moving average price of $233.20. The firm has a market cap of $46.61 billion, a PE ratio of 25.88, a PEG ratio of 1.54 and a beta of 0.44. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 1-year low of $172.41 and a 1-year high of $247.66.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same quarter last year, the firm earned $2.92 EPS. Cencora’s revenue for the quarter was up 10.8% compared to the same quarter last year. Research analysts predict that Cencora, Inc. will post 13.61 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is currently 22.32%.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at $63,323,746.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The disclosure for this sale can be found here. Insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799 in the last three months. 15.80% of the stock is currently owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.